Company / SG&A per Share
Oric Pharmaceuticals, Inc. SG&A per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.38
FY2025
5-year range
$0.38 / $0.63
FY2021-FY2025
Trend
-8.6%
vs FY2024
Sector context
#183 of 210
Health Care
What the data says
Oric Pharmaceuticals, Inc.'s sg&a per share of $0.38 is lower than 87% of companies in the Health Care sector (FY2025). SG&A per Share has declined for 3 consecutive years, from $0.63 in FY2022 to $0.38 in FY2025.
Based on SEC 10-K filings.
0.38 in FY2025 with a 5-year CAGR of -9.2%.
Improved from $0.50 to $0.38 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -15.8%
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 210This company $0.38 Sector average $40.75
▼
-99.1% below sector average
Key checks
Key Insights
- Oric Pharmaceuticals, Inc.'s sg&a per share has declined for 3 consecutive years.
- In FY2025, sg&a per share decreased 8.6% year-over-year.
- Ranks #183 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.38 | -8.6% |
| FY2024 | $0.41 | -16.9% |
| FY2023 | $0.50 | -21.3% |
| FY2022 | $0.63 | +9.1% |
| FY2021 | $0.58 | -5.2% |
| FY2020 | $0.61 | -79.7% |
| FY2019 | $3.01 | +56.3% |
| FY2018 | $1.93 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026